Georgia's Online Cancer Information Center

Find A Clinical Trial

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Status
Active
Cancer Type
Trial Phase
Phase III
Eligibility
18 Years and older, Female
Study Type
Treatment
NCT ID
NCT06132958
Protocol IDs
2870-005 (primary)
NCI-2024-02180
2023-504816-14
jRCT2031240041
U1111-1288-7581
Study Sponsor
Merck Sharp and Dohme LLC

Summary

Researchers are looking for new ways to treat people with endometrial cancer (EC) who
have previously received treatment with platinum based therapy (a type of chemotherapy)
and immunotherapy. Immunotherapy is a treatment that helps the immune system fight
cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy.
The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan
live longer overall and without the cancer getting worse compared to people who receive
chemotherapy.

Eligibility

  1. Has a histologically-confirmed diagnosis of endometrial carcinoma or carcinosarcoma.
  2. Has radiographically evaluable disease, either measurable or nonmeasurable per response evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central review (BICR).
  3. Has received prior platinum-based chemotherapy and anti-programmed cell death 1 protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination.

Treatment Sites in Georgia

Northside Hospital Cancer Institute


1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.